Equity Profile

CLDX

Celldex Therapeutics, Inc.

Health CareBiotechnology$3.0B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-1.10

Revenue

While specific revenue estimates are not available, any revenue growth would signal positive momentum in product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CLDX Q2-2026 Earnings Preview

Context

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. With a market cap of $3 billion, it operates in the health care sector, where advancements in biotechnology are crucial for improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.75%

Avg Stock Reaction

+3.90%

Last Quarter Recap

In Q1-2026, Celldex reported an EPS of $-1.18, which was worse than the expected $-1.10, leading to a 3.11% drop in stock price the following day. The company continues to face challenges in meeting earnings expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious as Celldex has missed EPS estimates in the past few quarters. The upcoming earnings report is critical for assessing the company's path forward.

Bull Case

If Celldex can surprise the market with better-than-expected EPS or positive developments in its pipeline, it could boost investor confidence and stock price significantly.

Bear Case

Conversely, continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to provide clear guidance.

Key Metrics to Watch

EPS (Earnings Per Share)

$-1.10

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

N/A

While specific revenue estimates are not available, any revenue growth would signal positive momentum in product development and market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in the pipeline?

The market will closely watch for any changes in timelines that could impact future revenue and growth potential.

Will there be any guidance on expected revenue for the upcoming quarters?

Clear revenue guidance can help investors gauge the company's financial health and operational effectiveness.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Celldex's pipeline to deliver unexpected results, especially given the volatility in the biotech sector.

Supporting Evidence

Options are pricing a 23.62% move, indicating significant expectations for volatility that may not align with historical performance.

Celldex has a mixed track record of surprises, with a 50% beat rate, suggesting potential for a positive surprise.

Key Risk

If the company provides strong updates on its pipeline, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Celldex can turn around its recent performance and provide a clearer path to profitability.

Bull Confirmed If

A surprise EPS of better than $-1.10 would signal improved operational efficiency and potentially boost investor sentiment.

Bear Confirmed If

An EPS worse than $-1.18 could indicate ongoing struggles and lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±23.62%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±23.6% while CLDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.3%

Calls (1K)P/C Ratio: 1.00Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celldex beats expectations, history suggests a potential stock increase of around 2.01%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react moderately, reflecting ongoing investor caution.

Miss

A miss could lead to a decline of about 5.80%, as seen in past reactions to disappointing earnings.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results for key therapies.
2Management's commentary on operational efficiencies and cost management.
3Details on partnerships or collaborations that could enhance growth.
4Guidance on future revenue expectations and timelines.
5Insights into market demand for Celldex's products.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-1.10

Revenue

While specific revenue estimates are not available, any revenue growth would signal positive momentum in product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CLDX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.75%

Avg Stock Reaction

+3.90%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious as Celldex has missed EPS estimates in the past few quarters. The upcoming earnings report is critical for assessing the company's path forward.

Bull Case

If Celldex can surprise the market with better-than-expected EPS or positive developments in its pipeline, it could boost investor confidence and stock price significantly.

Bear Case

Conversely, continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to provide clear guidance.

Key Metrics to Watch

EPS (Earnings Per Share)

$-1.10

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

N/A

While specific revenue estimates are not available, any revenue growth would signal positive momentum in product development and market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in the pipeline?

The market will closely watch for any changes in timelines that could impact future revenue and growth potential.

Will there be any guidance on expected revenue for the upcoming quarters?

Clear revenue guidance can help investors gauge the company's financial health and operational effectiveness.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Celldex's pipeline to deliver unexpected results, especially given the volatility in the biotech sector.

Supporting Evidence

Options are pricing a 23.62% move, indicating significant expectations for volatility that may not align with historical performance.

Celldex has a mixed track record of surprises, with a 50% beat rate, suggesting potential for a positive surprise.

Key Risk

If the company provides strong updates on its pipeline, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Celldex can turn around its recent performance and provide a clearer path to profitability.

Bull Confirmed If

A surprise EPS of better than $-1.10 would signal improved operational efficiency and potentially boost investor sentiment.

Bear Confirmed If

An EPS worse than $-1.18 could indicate ongoing struggles and lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±23.62%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±23.6% while CLDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.3%

Calls (1K)P/C Ratio: 1.00Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celldex beats expectations, history suggests a potential stock increase of around 2.01%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react moderately, reflecting ongoing investor caution.

Miss

A miss could lead to a decline of about 5.80%, as seen in past reactions to disappointing earnings.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results for key therapies.
2Management's commentary on operational efficiencies and cost management.
3Details on partnerships or collaborations that could enhance growth.
4Guidance on future revenue expectations and timelines.
5Insights into market demand for Celldex's products.